Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists

References

• Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull WHO. 2008;86:140–6.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Vaccines: The fourth century. ClinVaccine Immunol. 2009;16:1709–19.
   Web of Science ®Google Scholar
• Tan T, Dalby T, Forsyth K, Halperin SA, Heininger U, Hozbor D, Plotkin S, Ulloa-Gutierrez R, Wirsing von König CH. Pertussis across the globe: Recent epidemiologic trends from 2000 to 2013. Pediatr Infect Dis J. 2015;34:e222–32. doi:10.1097/INF.0000000000000795.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. The importance of persistence. Clin Infect Dis. 2016;63:S117–s8. doi:10.1093/cid/ciw525.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. The pertussis problem. Clin Infect Dis. 2014;58:830–3. doi:10.1093/cid/cit934.
   PubMed Web of Science ®Google Scholar
• Burdin N, Handy LK, Plotkin SA. What is wrong with pertussis vaccine immunity? The problem of waning effectiveness of pertussis vaccines. Cold Spring Harb Perspect Biol. 2017.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci. 2014;111:787–92. doi:10.1101/cshperspect.a029454.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Merkel TJ. The baboon model of pertussis: Effective use and lessons for pertussis vaccines. Expert Rev Vaccines. 2014;13:1241–52. doi:10.1586/14760584.2014.946016.
   PubMed Web of Science ®Google Scholar
• Allen AC, Mills KH. Improved pertussis vaccines based on adjuvants that induce cell-mediated immunity. Expert Rev Vaccines. 2014;13:1253–64. doi:10.1586/14760584.2014.936391.
   PubMed Web of Science ®Google Scholar
• Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci. 2009;30:287–95. doi:10.1016/j.tips.2009.03.005.
   PubMed Web of Science ®Google Scholar
• Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008;205:869–82. doi:10.1084/jem.20071087.
   PubMed Web of Science ®Google Scholar
• McKee AS, Burchill MA, Munks MW, Jin L, Kappler JW, Friedman RS, Jacobelli J, Marrack P. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Natl Acad Sci. 2013;110:E1122–31. doi:10.1073/pnas.1300392110.
   PubMed Web of Science ®Google Scholar
• Takeda K, Akira S. Toll-like receptors. Curr Protoc Immunol. 2015;109(14.2):1–0.
   Google Scholar
• Hoffmann J, Akira S. Innate immunity. Curr OpinImmunol. 2013;25:1–3.
   PubMed Web of Science ®Google Scholar
• Kumagai Y, Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol. 2010;125:985–92. doi:10.1016/j.jaci.2010.01.058.
   PubMed Web of Science ®Google Scholar
• Salunke DB, Shukla NM, Yoo E, Crall BM, Balakrishna R, Malladi SS, David SA. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides. J Med Chem. 2012;55:3353–63. doi:10.1021/jm3000533.
   PubMed Web of Science ®Google Scholar
• Salunke DB, Connelly SW, Shukla NM, Hermanson AR, Fox LM, David SA. Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. J Med Chem. 2013;56:5885–900. doi:10.1021/jm400620g.
   PubMed Web of Science ®Google Scholar
• Wu W, Li R, Malladi SS, Warshakoon HJ, Kimbrell MR, Amolins MW, Ukani R, Datta A, David SA. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides. J Med Chem. 2010;53:3198–213. doi:10.1021/jm901839g.
   PubMed Web of Science ®Google Scholar
• Salyer AC, Caruso G, Khetani KK, Fox LM, Malladi SS, David SA. Identification of adjuvantic activity of amphotericin B in a novel, multiplexed, Poly-TLR/NLR High-Throughput Screen. PLoS One. 2016;11:e0149848. doi:10.1371/journal.pone.0149848.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Kimbrell MR, Malladi SS, David SA. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline. Bioorg Med Chem Lett. 2009;19:2211–4. doi:10.1016/j.bmcl.2009.02.100.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Malladi SS, Mutz CA, Balakrishna R, David SA. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues. J Med Chem. 2010;53:4450–65. doi:10.1021/jm100358c.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Mutz CA, Ukani R, Warshakoon HJ, Moore DS, David SA. Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7. Bioorg Med Chem Lett. 2010;20:6384–6. doi:10.1016/j.bmcl.2010.09.093.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Lewis TC, Day TP, Mutz CA, Ukani R, Hamilton CD, Balakrishna R, David SA. Toward self-adjuvanting subunit vaccines: Model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines. Bioorg Med Chem Lett. 2011;21:3232–6. doi:10.1016/j.bmcl.2011.04.050.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Malladi SS, Day V, David SA. Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists. Bioorg Med Chem. 2011;19:3801–11. doi:10.1016/j.bmc.2011.04.052.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Mutz CA, Malladi SS, Warshakoon HJ, Balakrishna R, David SA. Toll-Like Receptor (TLR)-7 and −8 Modulatory Activities of Dimeric Imidazoquinolines. J Med Chem. 2012;55:1106–16. doi:10.1021/jm2010207.
   PubMed Web of Science ®Google Scholar
• Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS, David SA. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS One. 2012;7:e43612. doi:10.1371/journal.pone.0043612.
   PubMed Web of Science ®Google Scholar
• Yoo E, Crall BM, Balakrishna R, Malladi SS, Fox LM, Hermanson AR, David SA. Structure-activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines. Org Biomol Chem. 2013;11:6526–45. doi:10.1039/c3ob40816g.
   PubMed Web of Science ®Google Scholar
• Yoo E, Salunke DB, Sil D, Guo X, Salyer AC, Hermanson AR, Kumar M, Malladi SS, Balakrishna R, Thompson WH, et al. Determinants of activity at human Toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds. J Med Chem. 2014;57:7955–70. doi:10.1021/jm500744f.
   PubMed Web of Science ®Google Scholar
• Nuhn L, Vanparijs N, De Beuckelaer A, Lybaert L, Verstraete G, Deswarte K, Lienenklaus S, Shukla NM, Salyer AC, Lambrecht BN, et al. PH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proc Natl Acad Sci. 2016;113:8098–103. doi:10.1073/pnas.1600816113.
   PubMed Web of Science ®Google Scholar
• Salunke DB, Yoo E, Shukla NM, Balakrishna R, Malladi SS, Serafin KJ, Day VW, Wang X, David SA. Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines. J Med Chem. 2012;55:8137–51. doi:10.1021/jm301066h.
   PubMed Web of Science ®Google Scholar
• Kokatla HP, Yoo E, Salunke DB, Sil D, Ng CF, Balakrishna R, et al. Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines. Org Biomol Chem. 2013;11:1179–98. doi:10.1039/c2ob26705e.
   PubMed Web of Science ®Google Scholar
• Kokatla HP, Sil D, Malladi SS, Balakrishna R, Hermanson AR, Fox LM, Wang X, Dixit A, David SA. Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines. J Med Chem. 2013;56:6871–85. doi:10.1021/jm400694d.
   PubMed Web of Science ®Google Scholar
• Kokatla HP, Sil D, Tanji H, Ohto U, Malladi SS, Fox LM, Shimizu T, David SA. Structure-based design of novel human Toll-like receptor 8 agonists. Chem Med Chem. 2014;9:719–23. doi:10.1002/cmdc.201300573.
   Web of Science ®Google Scholar
• Beesu M, Malladi SS, Fox LM, Jones CD, Dixit A, David SA. Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines. J Med Chem. 2014;57:7325–41. doi:10.1021/jm500701q.
   PubMed Web of Science ®Google Scholar
• Beesu M, Kokatla HP, David SA. Syntheses of human TLR8-Specific small-molecule agonists. Methods Mol Biol. 2017;1494:29–44. doi:10.1007/978-1-4939-6445-1_3.
   PubMedGoogle Scholar
• Beesu M, Salyer AC, Trautman KL, Hill JK, David SA. Human Toll-like Receptor (TLR) 8-Specific agonistic activity in substituted pyrimidine-2,4-diamines. J Med Chem. 2016;59:8082–93. doi:10.1021/acs.jmedchem.6b00872.
   PubMed Web of Science ®Google Scholar
• Beesu M, Caruso G, Salyer AC, Khetani KK, Sil D, Weerasinghe M, Tanji H, Ohto U, Shimizu T, David SA. Structure-based design of human TLR8-Specific agonists with augmented potency and adjuvanticity. J Med Chem. 2015;58:7833–49. doi:10.1021/acs.jmedchem.5b01087.
   PubMed Web of Science ®Google Scholar
• Beesu M, Caruso G, Salyer AC, Shukla NM, Khetani KK, Smith LJ, Fox LM, Tanji H, Ohto U, Shimizu T, et al. Identification of a human Toll-Like Receptor (TLR) 8-Specific agonist and a functional pan-TLR Inhibitor in 2-aminoimidazoles. J Med Chem. 2016;59:3311–30. doi:10.1021/acs.jmedchem.6b00023.
   PubMed Web of Science ®Google Scholar
• Agnihotri G, Ukani R, Malladi SS, Warshakoon HJ, Balakrishna R, Wang X, et al. Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic gamma-glutamyldiaminopimelic acid derivatives. J Med Chem. 2011;54:1490–510. doi:10.1021/jm101535e.
   PubMed Web of Science ®Google Scholar
• Ukani R, Lewis TC, Day TP, Wu W, Malladi SS, Warshakoon HJ, David SA. Potent adjuvantic activity of a CCR1-agonistic bis-quinoline. Bioorg Med Chem Lett. 2012;22:293–5. doi:10.1016/j.bmcl.2011.11.014.
   PubMed Web of Science ®Google Scholar
• Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15:195–204. doi:10.1038/ni.2789.
   PubMed Web of Science ®Google Scholar
• Olafsdottir T, Lindqvist M, Harandi AM. Molecular signatures of vaccine adjuvants. Vaccine. 2015;33:5302–7. doi:10.1016/j.vaccine.2015.04.099.
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci. 2008;105:10501–6. doi:10.1073/pnas.0804699105.
   PubMed Web of Science ®Google Scholar
• Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Advances. 2017;1:2329–42. doi:10.1182/bloodadvances.2017011411.
   PubMed Web of Science ®Google Scholar
• Hood JD, Warshakoon HJ, Kimbrell MR, Shukla NM, Malladi S, Wang X, David SA. Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models. Hum Vaccin. 2010;6:1–14. doi:10.4161/hv.6.4.10866.
   Web of Science ®Google Scholar
• Salunke DB, Connelly SW, Shukla NM, Hermanson AR, Fox LM, David SA. Design and development of stable, water-soluble, human toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. J Med Chem. 2013.
   PubMed Web of Science ®Google Scholar
• Yoo E, Crall BM, Balakrishna R, Malladi SS, Fox LM, Hermanson AR, David SA. Structure-activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines. Org Biomol Chem. 2013;11:6526–45. doi:10.1039/c3ob40816g.
   PubMed Web of Science ®Google Scholar
• Kokatla HP, Sil D, Malladi SS, Balakrishna R, Hermanson AR, Fox LM, Wang X, Dixit A, David SA. Exquisite selectivity for human Toll-Like Receptor 8 in substituted furo[2,3-c]quinolines. J Med Chem. 2013;56:6871–85. doi:10.1021/jm400694d.
   PubMed Web of Science ®Google Scholar
• Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003;73:781–92. doi:10.1189/jlb.1202630.
   PubMed Web of Science ®Google Scholar
• Tran Vdu T, Souiai O, Romero-Barrios N, Crespi M, Gautheret D. Detection of generic differential RNA processing events from RNA-seq data. RNA Biol. 2016;13:59–67. doi:10.1080/15476286.2015.1118604.
   PubMed Web of Science ®Google Scholar
• Li X, Brock GN, Rouchka EC, Cooper NGF, Wu D, O'Toole TE, Gill RS, Eteleeb AM, O'Brien L, Rai SN. A comparison of per sample global scaling and per gene normalization methods for differential expression analysis of RNA-seq data. PLoS One. 2017;12:e0176185. doi:10.1371/journal.pone.0176185.
   PubMed Web of Science ®Google Scholar
• Stack EC, Wang C, Roman KA, Hoyt CC. Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. Methods (San Diego, Calif). 2014;70:46–58. doi:10.1016/j.ymeth.2014.08.016.
   PubMed Web of Science ®Google Scholar
• Chao J, DeBiasio R, Zhu Z, Giuliano KA, Schmidt BF. Immunofluorescence signal amplification by the enzyme-catalyzed deposition of a fluorescent reporter substrate (CARD). Cytometry. 1996;23:48–53. doi:10.1002/(SICI)1097-0320(19960101)23:1%3c48::AID-CYTO7%3e3.0.CO;2-I.
   PubMedGoogle Scholar
• He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11:477–88. doi:10.1080/21645515.2014.1004026.
   PubMed Web of Science ®Google Scholar
• Gupta RK. Aluminum compounds as vaccine adjuvants. AdvDrug DelivRev. 1998;32:155–72.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med. 2011;3:85ra48. doi:10.1126/scitranslmed.3002336.
   Web of Science ®Google Scholar
• El Sahly H. MF59 as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines. 2010;9:1135–41. doi:10.1586/erv.10.111.
   PubMed Web of Science ®Google Scholar
• Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180:5402–12. doi:10.4049/jimmunol.180.8.5402.
   PubMed Web of Science ®Google Scholar
• Von Oettingen WF, Todd TW, Sollmann T. The spreading and absorption of the different types of Bismuth preparations, introduced by intramuscular and subcutaneous injection. J Pharmacol Exp Ther. 1927;32:67.
   Google Scholar
• Ballard BE. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. J Pharm Sci. 1968;57:357–78. doi:10.1002/jps.2600570301.
   PubMed Web of Science ®Google Scholar
• Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997;151:317–22.
   PubMed Web of Science ®Google Scholar
• Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer. 2004;108:173–80. doi:10.1002/ijc.11542.
   PubMed Web of Science ®Google Scholar
• Witowski J, Thiel A, Dechend R, Dunkel K, Fouquet N, Bender TO, Langrehr JM, Gahl GM, Frei U, Jörres A. Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. Am J Pathol. 2001;158:1441–50. doi:10.1016/S0002-9440(10)64095-3.
   PubMed Web of Science ®Google Scholar
• Servais C, Erez N. From sentinel cells to inflammatory culprits: Cancer-associated fibroblasts in tumour-related inflammation. J Pathol. 2013;229:198–207. doi:10.1002/path.4103.
   PubMed Web of Science ®Google Scholar
• Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res. 2000;2:356–60. doi:10.1186/ar112.
   PubMedGoogle Scholar
• Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Murakami K, Miyake Y, Matsuo T. CXCL12 and CXCR4 expression by human gingival fibroblasts in periodontal disease. Clin Exp Immunol. 2005;141:467–74. doi:10.1111/j.1365-2249.2005.02852.x.
   PubMed Web of Science ®Google Scholar
• Diaz-Araya G, Vivar R, Humeres C, Boza P, Bolivar S, Munoz C. Cardiac fibroblasts as sentinel cells in cardiac tissue: Receptors, signaling pathways and cellular functions. Pharmacol Res. 2015;101:30–40. doi:10.1016/j.phrs.2015.07.001.
   PubMed Web of Science ®Google Scholar
• Almine JF, Wise SG, Hiob M, Singh NK, Tiwari KK, Vali S, Abbasi T, Weiss AS. Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts. FASEB J. 2013;27:3455–65. doi:10.1096/fj.13-231787.
   PubMed Web of Science ®Google Scholar
• Sunasara K, Cundy J, Srinivasan S, Evans B, Sun W, Cook S, Bortell E, Farley J, Griffin D, Bailey Piatchek M1, et al. Bivalent rLP2086 (Trumenba(R)): Development of a well-characterized vaccine through commercialization. Vaccine. 2017.
   PubMed Web of Science ®Google Scholar
• Luo Y, Friese OV, Runnels HA, Khandke L, Zlotnick G, Aulabaugh A, Gore T, Vidunas E, Raso SW, Novikova E, et al. The dual role of lipids of the lipoproteins in trumenba, a self-adjuvanting vaccine against meningococcal meningitis B disease. AAPS J. 2016;18:1562–75. doi:10.1208/s12248-016-9979-x.
   PubMed Web of Science ®Google Scholar